Skip to main content
hello world

Provided Content: Content provided by PR Newswire. The Globe and Mail was not involved, and material was not reviewed prior to publication.

Regulus Therapeutics Strengthens Research & Development Leadership

PR Newswire - Mon Jun 12, 2023

Appoints Preston S. Klassen, M.D., as President and Head of Research & Development

Curtis A. Monnig, Ph.D., named Vice President of CMC

SAN DIEGO, June 12, 2023 /PRNewswire/ -- Regulus Therapeutics Inc. (Nasdaq: RGLS), a biopharmaceutical company focused on the discovery and development of innovative medicines targeting microRNAs (the "Company" or "Regulus"), today announced the appointment of Preston S. Klassen M.D., M.H.S., to President and Head of Research and Development. Dr. Klassen brings over 20 years of experience in leadership roles in both large and small biopharmaceutical companies. In addition, the Company announced the appointment of Curtis A. Monnig, Ph.D., to Vice President of CMC. 

Read more at prnewswire.com